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Abstract 
Part A of the thesis is a protocol. The protocol outlines the background and the 
process of the research. The aim was to explore Human papillomavirus (HPV) 
prevalence among women following HPV vaccine introduction; the side effects and 
vaccination coverage. The vaccination coverage was measured as proportion of 
females who have received the recommended dose of the vaccine in a study.  The 
protocol follows the PRISMA guidelines. 
Part B is the thesis is an extensive literature review that explains the background, 
HPV vaccines currently available, HPV prevalence in the world, HPV vaccine 
implementing countries and considers the gaps in HPV vaccines literature. 
Part C of the thesis is a manuscript presented in the format suitable for Plos One 
journal submission. The background of the research is summarised and the methods 
and results are presented and discussed. 
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1. Background  
HPV is the most common, viral infection of the reproductive tract world-wide (1).The 
most common HPV types globally are HPV 16 and 18 which are strongly associated 
with the development of cervical cancer in women. In both men and women HPV 
types 6 and 11 are also common and strongly associated with genital warts (2). 
Although a majority of the HPV infections resolve on their own, constant infection 
may result in developing a disease (2). HPV has to be present in a cervical cancer 
diagnosis, HPV infections are therefore necessary for the development of cervical 
pre-cancer and cancer (3). Cervical cancer is also the second most frequently 
diagnosed cancer in women globally and more so in developing countries (3). 
Currently there are three vaccines recommended to prevent HPV related diseases, 
all three vaccines can be used in women but two are recommended for men (2), (4). 
All three licensed vaccines namely Gardasil, a quadrivalent vaccine; Cervarix, a 
bivalent vaccine and Gardasil, a 9 valent vaccine, cover at least two of the high risk 
HPV types 16 and 18. By 2014, 58 countries had introduced HPV vaccine in their 
national immunisation programme for girls (2). The World Health Organisation 
(WHO) recommends HPV vaccines be part of routine vaccinations for girls from the 
age of nine to thirteen years (2). Routine HPV vaccination covering more high risk 
types is said to be more effective in preventing cancer and less subject to variations 
in different regions (5).  
The introduction of a vaccine against human papillomavirus (HPV) has therefore 
been widely acknowledged as one of the greatest health care developments for 
women in recent years (6). Incidences of HPV related diseases caused by vaccine 
HPV types are projected to decrease in populations that have received the vaccine, 
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the biggest beneficiary being women, who have borne the brunt of HPV diseases 
over the years. As it stands, population studies are showing a decrease in vaccine 
type HPV prevalence among young girls since the vaccine was introduced (5). Many 
deaths will therefore be averted as a result of the vaccine as globally cervical cancer 
is estimated to cause 7.5% of all female cancer deaths, in 2012 alone an estimated 
266 000 globally deaths were from cervical cancer (2). The adjusted HPV prevalence 
globally among women with normal cytological findings was estimated to be 11.7%, 
according to a 5 continent meta-analysis (6).  
Female adolescents are the recommended target population for the vaccine (1). 
Particularly in young women, it has been found that the risk for HPV infection is 
mainly heightened soon after sexual debut; the peak prevalence of 24% has been 
observed in young women younger than 25 years (2). Extensive uptake of current 
HPV vaccines by young women could therefore reduce cervical cancer and mortality 
by roughly two-thirds (5).  
Evaluation of vaccine coverage has shown a big gap between developed and 
developing countries (6). A pooled analysis estimated from 2006 until 2014 has 
reported that 118 million women have been reached by vaccine programmes 
globally; however only 1% were from low-income or lower-middle-income countries 
(6). It is not surprising therefore that only a few developing countries to date are said 
to have undertaken national vaccination programmes (5). The highest HPV 
vaccination coverage in young women by 2014 was in developed countries where 
32.9% had been vaccinated, on the contrary developing countries had a coverage of 
2.7% (7). Vaccination coverage of at least 50% is estimated to reduce prevalence of 
HPV 16 and 18 by 68%, and reduction in anogenital warts by 61%. In low medium 
income countries, the introduction of vaccination on a large scale has so far been 
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limited or non-existent because vaccines were deemed too expensive (7). In Africa, 
where vaccination programmes are scant, the Global Alliance for Vaccines and 
immunisation (GAVI) has supported HPV vaccine rollout in support of HPV 
vaccination strategies in Africa (4).  
The review will be of potential interest in several areas globally. The review data will 
be used to help to inform the importance of HPV vaccination among the 
recommended age in a future national vaccination programme. On the other hand, in 
developed countries where the vaccine coverage remains high, this study will shed 
light on remaining questions about the indirect impacts of current and future HPV 
vaccines. The population effectiveness of HPV vaccines is currently an active area of 
research; therefore, we plan to review the currently available evidence on the effect 
of HPV vaccine uptake among female adolescents to prevent HPV infection. 
2.  Objectives  
To evaluate the effect of HPV vaccine uptake among female adolescents to prevent 
HPV infection 
3.  Methods  
3.1 Criteria for considering studies for this review  
3.1.1 Types of studies  
Randomised controlled trials (RCTs), cohort studies, control before and after (CBA), 
interrupted time series (ITS) and cross-sectional studies. 
3.1.2 Types of participants  
Females older than 9 years who received HPV vaccine.  
Page 13 of 102 
 
➢ 9 years of age is selected since it’s the recommended start age to receive 
vaccine at the adolescent phase. There is no maximum age limit. 
➢ Adolescents are defined as individuals aged 9 to 13 years; eligible for WHO-
recommended vaccines (2). 
3.1.3 Types of interventions  
Recommended HPV vaccines; quadrivalent vaccine, bivalent vaccine and 9valent 
vaccine. 
3.1.4 Types of outcome measures  
Primary outcomes  
Incidence or prevalence of HPV infection (proportion of females who developed HPV 
infection following vaccination). 
Secondary outcomes  
1. Vaccination coverage (the proportion of females who have received the 
recommended dose of the vaccine in a study) 
2. Cross protection Cost of the intervention. 
3. Adverse events following immunisation. 
4. Adverse effects of the intervention. 
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3.2 Search methods for identification of studies  
3.2.1 Search strategy 
We will develop a comprehensive search strategy to search both published and 
unpublished articles, with no restrictions on language or publication date. The 
strategy will include Medical Sub Headings (MeSH) and free-text terms relating to 
HPV vaccination uptake literature globally and will be adapted to suit each individual 
database using applicable controlled vocabulary.  
3.2.2 Electronic searches 
The peer reviewed articles in the following electronic databases will be screened: 
PubMed, Cochrane Central Register of Controlled Trials, Scopus, Web of Science, 
World Health Organisation Library Information System (WHOLIS), Africa Wide and 
Cumulative Index of Nursing and Allied Health Literature (CINAHL). We will search 
websites and databases for grey materials like WHO (http://www.who.int/), Global 
Alliance for Vaccine and Immunisation (GAVI) (http://www.gavialliance.org/), United 
Nations Children’s Funds (UNICEF) (http://www.unicef.org/), Program for 
Appropriate Technology in Health (PATH) Vaccine Resources Library 
(http://www.path.org/), US Centers for Disease Control and Prevention (CDC) 
(http://www.cdc.gov/), The communication initiative network 
(http://www.comminit.com/), http://www.nyam.org/library, http://www.opengrey.eu/, 
http://www.eldis.org/, Immunisation basics (http://www.immunizationbasics.jsi.com/ 
Index.html). Reference lists of relevant reviews and all eligible papers will also be 
searched for relevant studies. 
Page 15 of 102 
 
4. Data collection and analysis  
4.1 Selection of studies  
Two authors will independently screen abstracts and titles identified in the search 
results for eligible studies. The full text of studies that are eligible will be retrieved for 
assessment. Two of the authors reviewing the study will each independently apply 
inclusion criteria to the retrieved studies. Differences will be resolved through 
consensus between the two review authors. A third author’s opinion will be sought if 
consensus is not reached.  
4.2 Data extraction and management  
Two review authors will independently carry out data extraction using a standardized 
data extraction form. Disagreements will be resolved by consensus and the third 
author will be required if necessary to help resolve the issues. Prior to use, the 
extraction form will be piloted on at least four studies identified randomly from the list 
of included studies. The data extraction will include the following eligibility criteria: 
1. Study setting 
2. Study design 
3. Type of participants 
4. Vaccine type 
5. Details of outcome 
4.3 Assessment of risk of bias in included studies  
We will employ the quality assessment tool for evaluating prevalence studies as 
suggested by Hoy and colleagues and adapted by Werfalli and colleagues (8),(9). 
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The quantitative scoring system to the Risk of Bias criteria allocates four points for 
external validly and six points for internal validity. The scoring system tool 
categorises high risk studies as those with an overall score of 0-5 points, moderate 
risk as 6-8 and low risk > 8 points. Two review authors will apply the risk of bias 
criteria and we will discuss any disagreements through discussion and consensus, 
with the mediation of a third review author if required. 
4.4 Dealing with missing data  
Where necessary, the authors of the studies will be contacted for missing data. If the 
authors are not able to respond, the available data will be used and it will be stated 
that there are studies with missing data in the review. 
4.5 Assessment of heterogeneity  
If any variation in study results is experienced due to differences in the type of 
intervention, the type of setting, study design and risk of bias, we will describe in 
detail the variation. The result will not be pooled in case of substantial variation 
rather we will summarise in a narrative format (9). Statistical heterogeneity between 
study results will be assessed using the chi-squared test of homogeneity using a 
10% level of significance cut off. The I² statistic will be used where values of 25% 
reflect low heterogeneity, 50% medium heterogeneity and 75% reflect high 
heterogeneity.  
4.6 Assessment of reporting biases  
In order to assess risk of publication bias, we will use funnel plot to examine 
asymmetry provided there are 10 or more studies included. When we find evidence 
of small study effects we will consider publication bias as a possible explanation. A 
Page 17 of 102 
 
sensitivity analysis will be undertaken if plots suggest treatment effects may not be 
from a symmetric distribution. 
5. Data synthesis  
Data synthesis will comprise of two steps. The first step will be about identifying data 
sources, documenting the numerators and denominators that will be used for 
calculating prevalence. The second step is the use of the Freeman-Tukey double 
arcsine transformation to stabilise the variance of study prevalence using Stata® 
(version 13.1). The stabilisation of variance will help minimise influence from studies 
with outliers before the data is pooled together. Stratification of the data will be done 
by study design and samples sizes. 
5.1 Subgroup analysis and investigation of heterogeneity  
Subgroup analyses may be conducted if possible, taking into account but not limited 
to age of target population, vaccine given, setting of the studies and country income 
status. 
5.2 Subgroup analysis  
Where sufficient data are available, we will conduct subgroup analyses, which will 
explore the effects of vaccine given, setting of the studies and country income status. 
We will use the subgroup differences to test for subgroup interactions. Sensitivity 
analysis will be carried out to determine if the study designs, study period or 
publication type have an impact on the results of the meta-analysis. 
6. Assessing the of quality of evidence 
The basic principles of the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE)  approach will be used to assess the 
Page 18 of 102 
 
certainty of evidence of the included studies (10) We will set out the main findings of 
the assessment across studies in ’Summary of findings’ tables prepared using 
GRADE profiler software (11). We will GRADE the evidence as high, moderate, low 
or very low (10). High certainty evidence implies that “further research is very 
unlikely to change our confidence in the estimate of effect”. Moderate certainty 
evidence means that “further research is likely to have an important impact on our 
confidence in the estimate of effect and may change the estimate”. Evidence is 
considered of low certainty if “further research is very likely to have an important 
impact on our confidence in the estimate of effect and is likely to change the 




Page 19 of 102 
 
7. References 
1.  Monk BJ, Mahdavi A. Human papillomavirus vaccine: a new chance to prevent 
cervical cancer. Recent Results Cancer Res. 2007;174:81–90.  
2.  WHO. Human papillomavirus vaccines: WHO position paper, October 2014. 
World Heal Organ Wkly Epidemiol Rec [Internet]. 2014;89(43):465–92. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/24707510 
3.  Fischer S, Bettstetter M, Becher A, Lessel M, Bank C, Krams M, et al. Shift in 
prevalence of HPV types in cervical cytology specimens in the era of HPV 
vaccination. 2016;601–10.  
4.  Dailard C. Achieving Universal Vaccination Against Cervical Cancer In the 
United States: The Need and the Means. Policy Rev. 2006;9(4):12–6.  
5.  Lowy DR, Schiller JT. NIH Public Access. 2013;5(1):18–23.  
6.  Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical 
Human Papillomavirus Prevalence in 5 Continents: Meta‐ Analysis of 1 Million 
Women with Normal Cytological Findings. J Infect Dis [Internet]. 
2010;202(12):1789–99. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/21067372 
7.  Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. 
Global estimates of human papillomavirus vaccination coverage by region and 
income level: A pooled analysis. Lancet Glob Heal. 2016;4(7):e453–63.  
8.  Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of 
Page 20 of 102 
 
bias in prevalence studies: modification of an existing tool and evidence of 
interrater agreement. J Clin Epidemiol Elsevier Inc [Internet]. 2012;65(9):934–
939. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22742910 
9.  Werfalli M, Musekiwa A, Engel ME, Ross I, Kengne AP, Levitt NS. The 
prevalence of type 2 diabetes mellitus among older people in Africa: a 
systematic review study protocol. BMJ Open [Internet]. 2014;4(15):e004747. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/24939807 
10.  Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck- Y, Alonso-coello P, et al. 
Rating Quality of Evidence and Strength of Recommendations : GRADE : An 
Emerging Consensus on Rating Quality of Evidence and Strength of 
Recommendations RATING QUALITY OF EVIDENCE OF 
RECOMMENDATIONS GRADE : of evidence an emerging and consensus of 
on rati. Br Med J. 2008;336(April):924–6.  
11.  GRADEpro. Guideline Development Tool [Software] (developed by Evidence 
Prime [Internet]. McMaster University 2015. 2015. Available from: 
www.gradepro.org 
12.  Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. 
GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 
2011;64(4):401–6.  
 
Page 21 of 102 
 
8. Appendices  
8.1 Appendix 1: Search strategy 
PubMed search 





Search ((((((Human papillomavirus) AND Human 
papillomavirus[MeSH Terms)))) AND Human papillomavirus vacci*) 
AND ((Following OR after OR result OR impact))) AND ((Girls OR 
adolescent girls OR young women OR women))) AND ((Prevalence 
OR Incidence OR frequency OR distribution)) 
86 
Prevalence Search (Prevalence OR Incidence OR frequency OR distribution) 3894961 
Women Search (Girls OR adolescent girls OR young women OR women) 2527388 
Following Search (Following OR after OR result OR impact) 6004645 
HPV Vaccine Search Human papillomavirus vacci* 1949 
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8.2 Appendix2: Data extraction form 
Review title  
Study ID (e.g. Muusha 2016)  
A. General Information 
Date form completed (dd/mm/yyyy)  
Name/ID of person extracting data  
Reference citation  
Study author contact details  
Publication type 
(e.g. full report, abstract, letter) 
 
References of potentially eligible 




B. Study characteristics 
Study Characteristics Eligibility criteria Location in text  
Vaccine and disease 
targeted 
Cervarix-bivalent vaccine, Gardasil- quadrivalent 
vaccine, Gardasil - 9valent vaccine, for HPV 
vaccination 
 
Setting Studies in any country  
Study design Randomised controlled trials (RCTs), cohort studies, 
control before and after (CBA), interrupted time 
series (ITS) and cross-sectional studies 
 
Participants Women from the age of 9 years and above  
Types of outcome 
measures 
Primary outcome:  
Incidence or prevalence of HPV infection (proportion 
of females who received the recommended dose of 
the vaccine in a study). 
 
Secondary outcomes:  
1. Vaccination coverage (the proportion of females 
who have received the recommended dose of the 
vaccine in a study) 
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2. Cost of the intervention  
3. Adverse events following immunisation.  
4. Adverse effects of the intervention.  
Results Prevalence/incidence  
INCLUDE        EXCLUDE 
Reason for exclusion  
Notes:  
 
DO NOT PROCEED IF STUDY EXCLUDED FROM REVIEW 
C. Characteristics of study included 
Methods 
 
Descriptions as stated in report Location in text  








Length of participation 
  
Informed consent obtained Yes         No      Unclear 
 
Ethical approval obtained for 
study 



















Method/s of recruitment of 
participants 
  










Primary outcome: Prevalence of HPV infection following vaccination 
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Descriptions as stated in report/paper 
Key conclusions of 
study authors 
 
Study limits as 
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Appendix 3: Risk of Bias for Prevalence Studies 
 
External validity                            (1 = agree; 0= disagree) 
1. Was the study's target population a close 
representation of the national population in 
relation to relevant variables? 
1              0   
Support for judgment: 
2. Was the sampling frame a true or close 
representation of the target population? Yes No 
Unclear 
1              0   
Support for judgment: 
3. Was some form of random selection used to 
select the sample, or was a census 
undertaken? 
1              0   
Support for judgment: 
4. Was the likelihood of nonresponse bias 
minimal? 
 
Internal validity                            (1 = agree; 0= disagree) 
9. Was the length of the shortest prevalence 
period for the parameter of interest appropriate? 
1              0   
Support for judgment: 
5. Were data collected directly from the subjects 
(as opposed to a proxy)?  
1              0   
Support for judgment: 
6. Was an acceptable case definition used in 
the study?  
1              0   
Support for judgment: 
7. Was the study instrument that measured the 
parameter of interest shown to have validity and 
reliability? 
1              0   
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Support for judgment: 
8. Was the same mode of data collection used 
for all subjects?  
1              0   
Support for judgment: 
9. Was the length of the shortest prevalence 
period for the parameter of interest appropriate? 
1              0   
Support for judgement 
10. Were the numerator(s) and denominator(s) 
for the parameter of interest appropriate? 
1              0   
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1. Origins of HPV 
HPVs have evolved over millions of years to promulgate in a variety of animal 
species which include humans, the viruses are thought to have been linked to 
changes in the epithelium of their host in the first reptiles approximately 350 million 
years ago (1,2) . Viruses that evolve gradually with their hosts are known to be 
harmless and as such most HPV infection in humans resolve on their own, many 
HPVs therefore exist commensally within the human body and are not associated 
with disease(1,3,4).  
2. Biology of HPV and types 
HPVs are generally small of diameter 50-60nm, they are non-enveloped containing 
doubled strand closed circles of Deoxyribonucleic Acid (DNA) genome with 
approximately 8000 base pairs(1,4). Once infection is in the host cell nucleus, the 
virus survives as an independent episome; the life cycle of the virus however is 
facilitated by a chain of viral and host interactions which directs virion production, 
viral transcription and clearance of the majority of infections (5). The virus is 
protected by a capsid formed by two late proteins, Major Capsid Protein (L1) and 
Minor Capsid Protein (L2) structural proteins (1,6).  
The HPV genome is divided into three regions; the first is a noncoding upstream 
regulatory region which regulates the transcription of certain viral genes known as 
E6 and E7; the second region consists of six open reading frames which encodes 
structural proteins involved in viral replication and oncogenesis; the third region is 
responsible for encoding L1 and L2 structural proteins. 
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Figure 1: The structure of HPV. 
 
(Adapted from Swiss Institute of Bioinformatics, Viral Zone. - Available 
http://viralzone.expasy.org/5?outline=all_by_species 
As such, there are over 200 types papillomaviruses which have been identified and 
sequenced of which more than 150 are HPVs and over 100 are involved in human 
disease (1,2,7,8). The HPV types that cause disease are cutaneotropic, affecting the 
outer bodily skin, whereas other types are mucosotropic , affecting the skin the 
covers the internal organs such as cervix or mouth; there are however HPV types 
that can be found both in the cutaneous and mucosotropic layer (2). The various 
groups HPV types are found are tabled below; 
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Table 1: HPV group and type 
HPV group HPV type 
Cutaneotropic 1, 4, 5, 8, 41, 48, 60, 63 and 65 
Mucosotropic 6, 11, 13, 44, 55, 16, 31, 33, 35, 52, 58, 67, 18, 
39, 45, 59, 68, 70, 26, 51, 69, 30, 53, 56, 66, 
32, 42, 34, 64, 73, 54 
Cutaneotropic & mucosotropic 2, 3, 7, 10, 27, 28, 29, 40, 43, 57, 61, 62 and 72 
 
Cutaneous infections in humans are known to cause warts, cysts and skin cancer 
while mucosotropic HPV types are known to cause condyloma acuminatum, focal 
epithelial hyperplasia, cervical neoplasia and cervical cancer, anogenital cancers 
including and head and neck cancer. 
3. Epidemiology aspects of HPV infection 
Although many HPV types resolve on their own and are harmless, those that cause 
diseases have warranted the extensive study of HPV over the years. Of the over 100 
HPV types that are known to cause human disease, over 40 are thought to infect the 
genital tract (4,8). Specifically in women, HPV types that infect the female genital 
tract are known to cause precancerous and cancerous lesions of the cervix, 
condyloma acuminate and cancers of the lower genital tract (8). The most significant 
disease caused by HPV, cervical cancer, was first hypothesised by Italian physician 
to cause cancer linked with sexual behaviour (5). Infection by HPV is therefore 
basically a sexually transmitted disease, this has already been established. Risks of 
HPV infection are, early sexual debut, high number of sexual partners, sexual 
contacts with high risk individuals. In cervical cancer, factors such as genetic 
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predisposition, frequency of reinfection, coinfection with more than one HPV type, 
hormone levels and intertypic genetic variation with the HPV type itself have 
influence of the ability to clear an HPV infection (2) In light of HPV and women, it is 
therefore important to dwell more on HPV and cervical cancer which is the fourth 
most common cancer in women worldwide and the leading cause of cancer deaths 
among women in developing countries (3,9)  
4. HPV and cervical cancer 
In the development of cervical cancer, HPV DNA is required for the development of 
cervical cancer; over 90-100% of cervical cancer specimens have HPV (2,10) . This 
causal relationship was established in the 1990s, where molecular technology was 
able for the first time to provide evidence on the causal role of some HPV types in 
the development of cervical cancer (10). Of the HPV types that have been linked to 
cervical cancer, HPV 16,18,45 and 31 would explain approximately 80% of the 
cases, this information has been instrumental in the development of vaccines to 
prevent cervical cancer (2). HPV 16, 18, 45 and 31 as cancer causing agents will be 
beneficial in this systematic review, in the analysis of vaccine type prevalence as 
well as cross protective types. In fact, the associations between HPV and cervical 
cancer are noted as the highest ever in cancerology (2). Cervical cancer is initiated 
when HPV infects the cervical epithelium during mainly sexual intercourse, and 
despite many young people getting infected at sexual debut, it has been established 
that many of these infections do not develop into cervical cancer. Following the 
infection of the cervix, if there is persistent infection, cellular dysregulation will occur 
resulting in the formation of high grade cervical intraepithelial neoplasia; following 
this process would be the development of invasive cervical cancer. Throughout this 
process, the host immune system plays an vital role in the clearance or persistence 
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of infection as well as host genetic factors, cellular genetic changes and co-
carcinogens (7). 
That said, it is important to highlight that HPV infection is a necessary but not 
sufficient cause for infection. Acting in concert with high risk HPV types are 
additional factors such as sexual activity; the fact that a woman has a greater risk of 
getting infected if she has multiple sexual partners, or a partner of someone with 
many sexual partners; early sexual debut as well as previous infection with other 
sexually transmitted infections plays a role (7).  
Cervical cancer can thus be termed as a rare disease of a common infection 
because the development of cervical cancer itself takes a long time, usually decades 
(10-20 years), this presents a unique opportunity to intervene (6,7). The 
development of cervical cancer is ultimately dependent of the vivacity of the host 
immune system, women with a good immune system are able to clear HPV infection 
as 90% of the lesions regress naturally within 12 to 36 months (2). The importance of 
a strong immune system in the clearance of HPV has been shown in some studies 
looking at women living with HIV/AIDS, in immune compromised individuals, 
infection with high risk HPV types and their persistence is much more common than 
in immune competent individuals (3,7). This development is of particular importance 
for developing countries where HIV prevalence and incidence is high, hence the risk 
of women in these regions to develop cervical cancer is indeed high. The greatest 
risk of HPV infection is said to occur during metaplastic activity, which is, during 
puberty, at first pregnancy; however, despite the risk and infections occurring more 
frequently in younger ages, cervical cancer is common in older women as it has 
been proven to take years to develop. In light of this information, treatment and 
vaccination efforts can be age specific. 
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One of the important risk factors in cervical cancer development is persistent 
infection, especially when an infection is detected more than once every six months. 
The risk of developing cervical cancer with HPV 16 and 18 respectively is higher 
than other HPV types. HPV 16 in particular has been shown to reach higher viral 
loads compared to other HPV types and correlate with increased severity of cervical 
cancer, many studies have shown worldwide that HPV 16 and 18 are most prevalent 
(7,11,12). A significant factor that has been noted in HPV variants is how they vary 
geographically, for instance, five HPV 16 variants have been defined for Europe, 
Asia, Asian-American and African; as such Asian American variants are thought to 
have increased oncogenic virility compared to European as a result of increased 
transcriptional activity (11,13). In light of this evidence, HPV vaccinations currently 
available will be instrumental in ensuring countries are able to prioritise most fitting 
vaccine types for their country considering the most prevalent HPV types. 
Other cervical cancer risk factors are non-viral factors such as already postulated 
weak immune system due to not only HIV AIDS but conditions such as renal 
transplantation, increase risk of acquisition and progression of cervical cancer. The 
use of contraceptives, especially on a long-term basis; smoking, number of births a 
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5. HPV and other diseases 
Aside from cervical cancer, HPV is implicated to cause 20-90% of squamous 
carcinomas of the anus, oropharynx, vulva and vagina; in anal cancers, HPV type 16 
and 18 are responsible for an estimated 90% of the cancers and 40% of vulva 
cancers (3). The median infection time necessary for anogenital warts to develop in 
women is 5-6 months; anogenital warts are however not easy to treat and in some 
rare instances become malignant (14,15). HPV 6 and 11 are known to cause a rare 
condition called recurrent respiratory papillomatosis where warts develop on the 
larynx or any other part of the respiratory tract; this condition usually affects children, 
in rare instances this disease may be passed on to babies during childbirth.  
 
Numerous other diseases are caused by HPV, some of the prominent diseases 
affecting women will be mentioned in this section. Approximately 90% of anogenital 
warts are caused by HPV types 6 and 11 and in a systematic review the worldwide 
prevalence of anogenital warts was said to be between 0,13% to 0,20% (14). 
Worldwide the incidence of warts ranges from 160 to 280 per 100 000; in women to 
be precise, the incidence of warts is higher than in men, with a median age of 120,5 
per 100 000 (14). By region new anogenital warts incidence for North America 
ranged from 101 to 205 per 100 000 population, Europe ranged from 118 to 170 per 
100 000 population and in Asia 204 per 100 000 population (25–27). Anogenital 
warts are said to be extremely infectious, as 65% of people with an infected 
companion develop anogenital warts within 3 weeks and 8 months (28) 
Options to treat anogenital warts are available but are known to have high recurrent 
rates after treatment (29–31). The available options for treatment include home 
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based (podofilox and imiquimod) as well as physician based chemical treatments 
(podophyllin, trichloracetic acid, interferon, green tea extract) there are also ablative 
treatments (cryotherapy, surgical removal, laser treatment) (14,32). In addition to the 
available options, there are preventative options in the form of the quadrivalent 
vaccine which has demonstrated efficacy in preventing the HPV types 6 and 11 
related anogenital warts (33). 
6. Diagnosis and treatment options for HPV and cervical cancer 
Screening and treatment for preinvasive cancer of the cervix is very effective in 
averting advancement to cervical cancer(16). Cytology and visual inspection with 
acetic acid are the main methods of cervical cancer screening; visual inspection is a 
popular method used in low resource countries. Early detection of precancerous 
changes is detected through screening at peak ages of cervical cancer incidence; 
the screenings allow for the detection of any changes which may lead to the disease 
(6). Tests that are based on HPV DNA are used and performed on cervical or 
vaginal swabs; a microscopic examination of the exfoliated cells detects changes in 
the cervical epithelium.  
HPV infections can be treated by tissue destructive methods as there is no virus 
specific treatment. Cryotherapy, surgical excision of the affected tissue, excision by 
cone biopsy are some of the methods used to treat precancerous lesions. In 
addition, radiotherapy, brachytherapy, radical surgery and chemotherapy can be 
effectively used to treat cancer, especially when disease is still localised (6). Even 
though these options are effective, developing countries have been unable to 
consistently apply then so as to reap the benefits, the cost of some of the options 
have been too high for some developing countries with competing health 
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interests(6,12); vaccination is another option that has be added to the cocktail of 
current interventions whose promise we hope to further illuminate in this study  
7. HPV Vaccines 
There are currently 3 vaccines licenced for distribution worldwide; that is, a 
quadrivalent vaccine, bivalent vaccine and nonavalent vaccine, all the vaccines 
focus on the oncogenic HPV genotypes. First to be licenced was the quadrivalent 
vaccine in 2006, the vaccine aims to protect against HPV 6, 11, 16 and 18; in 2007 
the bivalent vaccine was introduced, protecting against HPV types 16 and 18 and 
most recently in 2014 the nonavalent vaccine was approved by the FDA which 
focuses of protecting against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. All the 
vaccines are recommended to be administered before sexual debut as this 
maximises vaccine effectiveness (3,17). HPV vaccines have been found to be most 
effective in people who have not been previously exposed to the HPV virus. 
Targeting older populations poses a risk of wasting resources as this population has 
most likely been exposed to the HPV virus which reduces the HPV vaccine’s 
effectiveness(3).  The reason why HPV vaccination is more effective in uninfected 
individuals than those infected, is still the subject of debate, Schiller theorises that 
the HPV vaccine works in uninfected individuals because of the high antigen dosage 
and method of administration which target the blood stream (18). When compared 
with the HPV vaccine, an individual’s immune system’s response to HPV infection is 
considered to be weak. It is argued that the HPV natural immune system is not 
bolstered by high virus dosage so as to activate strong immunity, the natural HPV 
exposure to the immune system is usually of low dose and also because HPV 
infections are limited to epithelial surfaces (18). 
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The quadrivalent vaccine is injected intramuscularly and contains purified viral 
proteins meaning that they do not have live biological products or viral DNA. The 
vaccine is created using yeast substrate and includes amorphous aluminium 
hydroxyphosphate sulphate, each the vaccine contains HPV-6 L1 protein, HPV-11 
L1 protein, HPV-16 L1 protein and HPV-18 L1 protein which gets absorbed onto the 
adjuvant (3,19). The second dosage of the vaccine follows the first in the second 
month and the last vaccine at six months. The vaccine is indicated for use in females 
and males from the age of 9 years to prevent premalignant genital and anal lesions, 
cervical and anal cancers and anogenital warts (3). The bivalent vaccine is injected 
intramuscularly, also contains purified viral proteins for the two HPV types. Prefilled 
syringes or vials are used as a single or two dose with the second dose given after 
one month of the first and third at six months (6). The vaccine dose of 0.5 ml 
contains HPV-16 protein, HPV 18 LI protein absorbed into and adjuvant system 
containing aluminium hydroxide and monophosphotyl lipid (6). The vaccine is 
indicated for use in girls of the ages 9 years to prevent genital lesions cervical cancer 
related to HPVs 16 and 18. In resource constrained settings however, the 
recommendation is that girls under the age of 15 receive the 2-dose schedule with a 
6-month interval between first dose, if the interval between first dose is less than 5 
months, a third dose is recommended but only in immunocompromised (16). This 
recommendation is based on studies that have shown little difference between 
immune response in those who received 2 or 3 dose schedules, in countries with 
limited resources, opting for the two-dose schedule would therefore be cost effective 
(20,21). 
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The nonavalent vaccine is also a non-infectious, virus-like particle which can be 
injected intramuscularly the vaccination is recommended be initiated from age 9 to 
26 years, it is recommended to be administered in a 3-dose schedule with the 
second dose following the first at two months and the third dose at six months (3). 
Currently the bivalent and quadrivalent vaccine have been used in many settings, in 
the studies analysed, there was no study reporting nonavalent use. Since the 
nonavalent vaccine was approved in 2014, it makes sense that it will take a while 
until any HPV prevalence studies associated with national rollout will come after a 
few years. 
8. Impact and cost effectiveness of the vaccines 
All vaccines are expected to reduce incidence of HPV16 and 18 thereby preventing 
cervical cancer and cervical adenocarcinoma related to HPV 16 and 18 as well as 
other cancers related to the HPV types such as head and neck cancer or anal 
cancer (6). Mortality reductions are expected to benefit low and middle-income 
countries (LMICs) as they have limited screening, hence vaccine coverage and 
duration will be critical in determining vaccine impact assuming that efficacy is high. 
Vaccination is expected to reduce lifetime risk of cervical cancer by 35 to 80%; in the 
Global alliance for vaccines and immunisation eligible countries with coverage of 
70%, over a million women’s lives are expected to be saved (6). In a systematic 
review considering global cost effectiveness of the HPV vaccine, 25 of 26 studies 
concluded that vaccinating young girls is likely to be most cost effective, especially 
when done in resource constrained settings where there is limited coverage of 
cervical cancer prevention and control measures (22) 
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9. HPV in the world and its overall prevalence, mortality and morbidity 
80% of women in the world will at some point in their life get an HPV infection, of the 
women who will get infected, 10% will harbour cervical HPV types at any given time, 
arguably in another meta-analysis, the percentage of women estimated to carry HPV 
16 and 18 DNA worldwide is 32% (12,23,24) Based on a 5 continental meta-
analysis, women with normal cytological findings had an adjusted HPV prevalence of 
11, 7% with a 95% CI of 11,6% to 11,7% and a study by de Sanjose et.al looking at 
worldwide HPV prevalence showed women with normal cytology to have 10.4% 
prevalence with a 95% CI of 10.2 to 10,7% (11,12). Worldwide, women between the 
age of 15 and 25 years stand the highest risk of HPV infection while older women 
stand the highest risk of developing cervical cancer(11,24).  
In one study HPV prevalence in Africa was found to be 22.1%, while another 
reported HPV prevalence in Africa ranging between 7% to 60% with over half of the 
studies having a prevalence less than 20%; regionally in Africa the highest HPV 
prevalence according to the 5 continental analysis was Sub-Saharan Africa, where 
the adjusted prevalence was found to be 24% (11,12,24). Africa thus far has the 
highest HPV prevalence with each study examined worldwide. It also goes without 
saying that Sub-Saharan Africa, the Caribbean and Latin America account for the 
highest incidence rates of cervical cancer, most of the cervical cancer deaths 
however occur in India, with approximately 123000 new cases diagnosed a year with 
more than 67000 women dying from the disease (25). Compared to the rest of the 
world, in the 5 continental meta-analysis, Africa’s HPV prevalence was followed by 
Latin America and the Caribbean with 16,1%; Eastern Europe with 14,2% and South 
East Asia with 14% (11). Asia seems to generally have low HPV prevalence, this 
was also highlighted in the de Sanjose et.al meta-analysis where Asia’s HPV 
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prevalence was found to be 8% with a 95% CI of 7,5% to 8,4%(12). In the 5 
continental meta-analysis, when HPV prevalence was considered by country, 
prevalence would range between 1, 6% to 41, 9%, there was a huge variation which 
speaks to the inequality in the distribution of resources in countries, this is also 
evident among regions where LMICs have the highest prevalence of HPV. That said, 
high risk regions for cervical cancer are East African countries, Melanasia, Southern 
African countries and middle Africa; the lowest cervical cancer rates were found to 
be in Australia and Western Asia(11). HPV types that were found common worldwide 
in the 5 continental meta-analysis were HPV types 16, 18, 52, 31, 58, 39, 51, and 56 
, these types are also responsible for 90% cancerous cells; the most frequent HPV 
types worldwide however were found to be HPV 16 and 18 and it has been so since 
1940 (3,11). Considering age specific HPV distribution by region, in a systematic 
review done considering age specific prevalence worldwide, HPV prevalence 
constantly peaked in women younger or 25 years old, decreasing afterwards with 
age(24). In the study, Central and South America and Africa’s age curves showed an 
additional increase of HPV prevalence in women 45 years and older, this second 
and most pronounced peak is thought to reflect differences in sexual behaviour 
across regions, or reactivation of latent HPV infections in older women (12,24).  
Compared to uninfected women, the risk of developing squamous cell carcinoma of 
the cervix increases by approximately 400 times when the HPV type of infection is 
HPV 16 and 250 times higher is HPV type is 18 (3) Despite these alarming odds, the 
chance of a women living in less developed regions to develop cervical cancer is as 
small as 2%, this is because infection with HPV does not always lead to cancer as 
infections are short lived, furthermore, infection persists only in a small percentage of 
Prudence Muusha: Literature Review   
 
Page 42 of 102 
 
women infected with high risk HPV types , which may progress to pre cancer and an 
even smaller number into cervical cancer. 
As highlighted before, less developed regions have the highest prevalence of HPV, 
this prevalence accounts for more than 80% of cervical cancers in the regions. In 
developing regions, cervical cancer accounts for 12% of all female cancer mortalities 
(3). Mortality however differs by different regions, it is estimated mortality rates vary 
18 fold between regions, with less than 2 deaths per 100 000 women in 
industrialised countries and greater that 20 per 100 000 in some developing 
countries (26). 
The WHO position paper proposes that HPV vaccines need to be introduced as part 
a coordinated and comprehensive strategy to prevent cervical cancer and related 
diseases, the strategy will include educating general masses around behaviours that 
lower risks, training of health workers, and giving women information about 
screening, diagnosis and treatment about cancer and related lesions (3). HPV 
vaccination is recommended by WHO for girls aged 9 to 13 years (16).  
That said, the implementation of HPV vaccines began in 2006 mainly targeting 
young girls of ages 10-14 years. According to cervical cancer action, 69 countries as 
of June 2017 have implemented HPV vaccination on a national scale while 38 
countries have implemented pilot programmes; the continents that have introduced 
most of the national HPV vaccination are North America, South America, Europe, 
and Australia while Africa has mostly implemented pilot programs (38). 
High income countries have thus had the advantage of resources and finance 
needed to implement vaccination so early on, while LMICs have had to depend on 
donor funding and pilot projects to implement, this despite that the biggest need is in 
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middle to low income countries. LMICs face unique challenges in rolling out HPV 
vaccination.  These comprise health system challenges which include cost and 
delivery logistics, socio cultural resistance around fear of infertility, as well as lack of 
political will to invest in HPV vaccination against other pressing priority health issues 
such as AIDS treatment (39,40). 
 A systematic review has estimated that worldwide, not less than 118 million people 
have been targeted for vaccination by a vaccination program between 2006 and 
2014; of the targeted population 62 million is said to be the primary target, the 
numbers are said to only represent 3,5% of females globally; 82% of the HPV 
vaccination targeted population was from developed regions while 18% from the less 
developed regions (41) High income countries have nevertheless shown vaccination 
coverage of less than 50% as a result of some countries that are underperforming 
such as France and United States of America. In developing countries, however, 
coverage levels in the few countries that implemented were higher; considering the 
21 demonstration projects from 14 countries, HPV vaccination uptake rate was 
88.7% (41). 
10. HPV prevalence in Africa 
Africa has the highest HPV prevalence compared to other continents, and thus 
specific focus will be in zooming into the HPV prevalence and current HPV 
vaccination progress in this continent. In Africa, the most prevalent HPV type 
according to a 5 continental meta-analysis is HPV 16, which has a prevalence of 
3,5% the highest among other oncogenic types(11). Based on a systematic review 
done on African women with normal cytological findings the most prevalent HPV 
types identified included HPV 16, which was the most prevalent HPV type followed 
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by 52,35,18,58,51,45,31,53 and 56 in descending order and the age group with the 
highest HPV prevalence was the 25-34 years age group with 50,5% prevalence (27). 
When infection was considered by region, Southern Africa had the highest HPV 
prevalence with a prevalence of 57,3%, followed by East Africa with 42,2%, Western 
Africa with 27,8% and the lowest in Northern Africa where there was a 12,8% HPV 
prevalence (27) It is also imperative to highlight that HPV 16 and 18 in women with 
normal cytology was higher in Sub Saharan women compared to other regions with 
a prevalence of 9.9% and 5.8% respectively; this is much higher the continental 
average as indicated in the 5 continental meta-analysis where HPV 16 had a 3,5% 
prevalence(11,27).  
Sub-saharan Africa therefore clearly has the biggest burden to reduce infection in 
the prevalence of cervical cancer causing HPV types 16 and 18, the effort by South 
Africa in using bivalent vaccine in its national rollout is one testament to this 
reality(27,28). Screening programs have especially been difficult to implement in Sub 
Saharan Africa as a result of competing interests, more so vaccination. HIV AIDS 
has been on the priority agenda for many sub-Saharan Africa countries, cervical 
cancer and screening therefore just had to take a back seat(29). HPV surveys in 
some sub Saharan African countries have shown a prevalence of 40% in 
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Figure 2: Global progress in HPV vaccination 
 
(31)"Source: Cervical Cancer Action." 
Vaccine demonstration projects in India, Peru, Uganda and Viet Nam from 2008 until 
2010 using the Expanded Programme on Immunisation (EPI) and using WHO 
guidelines showed high coverage of the HPV vaccine in Viet Nam of 98.6% (25). A 
caveat about EPI data is its unreliability, when compared to surveys, routine 
administrative reports often overestimate coverage levels. The reliability of EPI data 
is compromised by service providers often report crude coverage instead of valid 
coverage, poor data quality, weak information systems and service providers 
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intentionally inflating numbers (32,33).  In South Africa, where cervical cancer is the 
second most common form of cancer in women and transects with high HIV/AIDS 
prevalence, a recently rolled out national immunisation programme is showing high 
uptake of the vaccine. In the demonstration project prior to national rollout of 
vaccination there was a more than 96% vaccine uptake; this level of uptake has 
been consistently shown in countries such as Bolivia and Uganda where uptake was 
over 90%. (34). 47 million women are estimated to have been vaccinated against 
HPV with a full dose through various immunisation programs by 2015, representing 
1,5% of the total female population (35) HPV coverage of 70% is regarded as the 
threshold for cost effectiveness, whilst coverage by at least 50% in a meta-analysis 
resulted in 68% reduction on HPV types 16 and 18 and reduced anogenital warts by 
61%(35). 
More than any other cancer, cervical cancer shows a striking global health inequality, 
the impact has been illuminated in developing countries, it is therefore imperative 
that focus is on how developing countries can use various strategies to implement 
vaccination as well as look at their challenges. In the WHO position paper of 2014, 
they suggest that HPV vaccine be implemented using approached that are 
compatible with their delivery infrastructure and cold chain capacity, affordable and 
cost effective as well as sustainable, and are most likely to achieve the highest 
possible coverage(3). Consideration in the implementation of HPV vaccination will 
need to consider affordability, cost effectiveness, cultural acceptability, political will 
and support from the public(36). Policy makers also need to consider the disease 
burden, health care infrastructure and the ability to initiate and sustain vaccination 
programs; this is already problematic in developing countries where health resources 
continue to be very limited considering the need. 
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All countries have a national immunisation program delivering vaccines funded by 
the government of the country. In developing countries however, the lead in the roll 
out of HPV vaccination was led by GAVI an organisation in support of vaccination 
globally. Success with GAVI implementation has already been seen in the hepatitis B 
vaccine in over 40 countries where there was improved coverage, financing, 
infrastructure and information systems (37). The GAVI HPV vaccine programme has 
48 countries which it has identified as eligible for HPV vaccine introduction with the 
assistance of GAVI financing, all these countries are in developing countries. GAVI 
Alliance support has seen national rollout of HPV vaccine in Uganda, Bolivia, 
Guyana, Honduras, Sri Lanka, Uzbekistan and Rwanda; Rwanda was the first 
African country to implement HPV vaccination, which had already implemented a 
successful demonstration project (38). GAVI Alliance as of 2017 has also seen to the 
implementation of 28 demonstration programmes in the eligible countries (38) 
 Low and middle income countries face social cultural barriers mainly due to the fact 
that it is a vaccine against STI something which holds as taboo and has connotations 
of promiscuity for many; health system barriers as a result of insufficient 
infrastructure and human resources; political barriers as a result of lack of political 
will and investment, competing health priorities and the involvement of 
stakeholders(39) A study in Mali regarding attitudes towards HPV vaccination 
interestingly found out that 59% of the women in their study would need consent 
from their male counterparts in order to be vaccinated(40) 
As a result, there is no prevalence data following vaccination from developing 
countries, in the developing countries, many countries as illustrated have 
implemented but however, few studies have been done to monitor vaccine 
prevalence following implementation. Countries that benefited in early rollout of HPV 
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vaccination like the United States and Australia are producing encouraging results of 
HPV vaccination. In this systematic review from the data collected in the studies 
monitoring HPV prevalence after vaccination, the hope is to add to evidence, a more 
comprehensive outlook on the performance of HPV vaccination thus far. 
11. Summary and conclusion of the literature review 
HPV is a common sexually transmitted infection with the highest prevalence among 
women during sexual debut. HPV is well known to cause among other diseases 
cervical cancer and certain HPV strains can be targeted by vaccines to ameliorate 
cervical cancer and genital warts. HPV vaccines have been available on the market 
since 2006 and a number of developed countries have already implemented national 
vaccination programs with varying coverages and successes.  
Reviews considering developing countries especially Africa are therefore much 
needed. National HPV vaccination data in developing countries in scarce and most 
developing countries are yet to introduce a national HPV vaccination programme. 
Vaccination coverages in developing countries have however been more promising 
than current coverages seen in developed countries. Developing countries will 
therefore have a unique opportunity to maximise the benefits of the HPV vaccine 
among their populations. Developing countries have the most need for the vaccine 
due to highest HPV prevalence and cervical cancer mortalities being recorded in the 
regions. The HPV has been out of reach for most developing countries because of 
high vaccine costs and competing health interests. We therefore undertake a 
systematic review on HPV prevalence following HPV vaccination in women around 
the world. The review will add onto the active area of research around HPV 
Prudence Muusha: Literature Review   
 
Page 49 of 102 
 
vaccination impact as well as hopefully inform clinical practice and policy in countries 
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Abstract 
Background: Worldwide efforts have been made by some countries to offer HPV 
vaccination since its introduction in 2006. Population effectiveness of HPV vaccines 
is presently an active area of research. We review available evidence on the 
effectiveness of HPV vaccine uptake among young women to prevent HPV infection. 
Methods: A comprehensive search of published and grey literature was conducted 
in several electronic databases using a pre-defined search strategy related to HPV 
prevalence following vaccination. The database searches were complemented by 
hand-searches of reference lists of eligible studies. Data were extracted onto a 
purpose-designed data extraction form, pooled in a meta-analysis and stratified by 
continent considering vaccine type, cross protective and (high/low) risk HPV types as 
subgroups. 
Results: Our search yielded 1680 studies, of which thirteen met with our inclusion 
criteria (8332 vaccinated women aged 12 to 34 years from across the world). The 
pooled HPV (comprising types 6, 11, 16 and 18) prevalence among young 
vaccinated women was 7% (95% Confidence Interval (CI): 5% to 9%, 13 studies, 
n=8,332). The 13 studies were conducted across 3 continents: HPV prevalence for 
North America was 5% (95% CI: 3% to 7%, 9 studies, n=5781, age range =13 to 34); 
Europe, 14% (95% CI: 9% to 18%, 3 studies, n=2213, age range =13 to 29) and 
Australia 5% (95% CI: 3% to 8%, 1 study, n=5781, age range=13 to 34). Of the 
studies which reported the effect of vaccination on other non-vaccine HPV type 
prevalence (known as cross protective types)HPV (31, 33, 45, 51 & 58), the overall 
pooled cross protective HPV prevalence was 9% (95% CI: 6% to 12%, 4  studies, 
n=3081 age range=13 to 29), by continent North America had 14% (95% CI: 12 to 
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17%, 1 study, n=753 age range=14 to 24), Europe 7% (95% CI: 6 to 8%, 2 studies, 
n=1990, age range=13 to 29) and Australia with 8% (95% CI: 5% to 11%, 1 study, 
n=338 age range=18 to 26). 
Conclusion:  This study showed an HPV prevalence of 7% in women vaccinated 
against HPV types 6, 11, 16 and 18, which represents a substantial difference to the 
22% HPV prevalence in non-vaccinated women. There is however, still a dearth of 
information on vaccinated women and HPV prevalence, highlighting the need for 
further studies in this area. 
Strengths and limitation of this review 
• The review comprehensively searched multiple databases and bibliographies. 
We had no language restrictions. 
• We were stringent in the selection of studies as far as vaccination status was 
concerned. Studies considering HPV prevalence in unvaccinated women 
were excluded. 
• A variety of methods was utilised in collecting data across the studies. 
However, some of the study participants were not representative of the 
general population. Caution therefore, needs to be considered when using 
these results to make inferences or conclusions about prevalence of certain 
populations. 
Keywords: Human papillomavirus, HPV prevalence, HPV vaccine type, Women 
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1. Background 
The introduction of a vaccine against the types of human papillomavirus (HPV) which 
are linked to most cases of cervical cancer, is widely considered to be one of the 
greatest health care developments for women in recent years (1,2). Cervical cancer 
is currently the fourth most frequently diagnosed cancer in women globally and more 
so in developing countries where it is the leading cause of cancer mortality, in Sub-
Saharan Africa it is the leading cause of all cancer deaths in women (3–5). Although 
a majority of the HPV infections resolve on their own, constant infection may result in 
developing a disease (3,6). Globally the most common HPV types which are strongly 
associated with the development of cervical cancer are HPV 16 and 18 (3,7,8). HPV 
has to be present in a cervical cancer diagnosis, HPV infections particularly high-risk 
types are necessary for the development of cervical pre-cancer and cancer. HPV 
types 6 and 11 are known  to cause genital warts, in both women and men (9,10). 
Advancements in HPV prevention have to date resulted in the development of 
vaccines targeting high risk HPV types, with the most recent vaccine targeting 9 HPV 
types, HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 (11,12). Currently there are three 
vaccines recommended to prevent HPV related diseases, namely quadrivalent, 
bivalent and nonavalent vaccine;  all three vaccines can be used in women but only 
two are also recommended for use in men (3,11) . Table 1 shows vaccines currently 
available. 
Table 1: HPV vaccine available 
 Formulation HPV type Year approved 
1 Quadrivalent 6,11,16 and 18 2006 
2 Bivalent 16 and 18 2009 
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All the vaccines cover at least two of the high risk HPV types 16 and 18 (3,11,13). 
The vaccines have also been proven to have cross protection on HPV types 
31,33,45,51 and 58.  HPV vaccination progress has been slow, especially for 
developing countries; by 2017, 64 countries, mainly in developed countries had 
introduced HPV vaccination into their national immunisation programme (14). 
The risk for HPV infection begins soon after sexual debut with the peak prevalence 
of 24% observed in young women under 25 years. The World Health Organisation 
(WHO) therefore recommends HPV vaccines be part of routine vaccinations for girls 
from nine to thirteen years of age (3). Extensive uptake of current HPV vaccines by 
young women could therefore potentially reduce cervical cancer and mortality by 
roughly two-thirds (15). In addition, routine HPV vaccination covering more high risk 
types would be more effective in preventing cancer and less subject to variations in 
different regions (16). 
Incidences of HPV-related diseases caused by vaccine HPV types are projected to 
decrease in populations that have received the vaccine, especially in women (15). 
To date, population studies are showing a decrease in vaccine type HPV prevalence 
among young girls since the vaccine was introduced (15,17). Many deaths will 
therefore be averted because of the HPV vaccine introduction. Globally cervical 
cancer is estimated to cause 7.5% of all female cancer deaths. In 2012 alone an 
estimated 266 000 globally deaths were from cervical cancer (3). The adjusted HPV 
prevalence globally among women with normal cytological findings was estimated to 
be 11.7%, according to a 5 continent meta-analysis, but most of the high risk HPV 
prevalence was identified in developing countries where HPV prevalence in Africa 
was found to be highest at 22.1% (8). 
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Assessment of vaccine coverage currently shows a gap between developing and 
developed countries, therefore, cervical cancer has been said to be a health 
condition that is indicative of health inequalities in the world (8,15). Developing 
countries are indeed lagging behind with HPV vaccination despite having the most 
need; in a pooled analysis of data from 2006 to 2014, it is reported that 118 million 
women have been reached by vaccine programmes globally; however only 1% were 
from low-income or lower-middle-income countries (8). A few demonstration projects 
have been implemented in developing countries. The demonstration projects show 
high vaccine coverage when compared with developed countries despite developed 
countries having implemented national vaccination programmes.  
Based on good coverage in the demonstration projects in developing countries, there 
is much hope for vaccine benefits once developing countries are able to rollout 
national HPV vaccination. It has been further highlighted that by 2014, the highest 
HPV vaccination coverage was in young women from developed countries where 
32.9% had been vaccinated; on the contrary developing countries had a coverage of 
2.7% (18). Vaccination coverage of at least 50% is estimated to reduce prevalence 
of HPV 16 and 18 by 68%, and reduction in anogenital warts by 61% (16). In 
developing countries the introduction of vaccination on a large scale has so far been 
limited because, amongst other reasons, vaccines were deemed too expensive (18). 
Vaccination programmes in developing countries are scant and the few implemented 
were demonstration projects spearheaded by the Global Alliance for Vaccines and 
immunization (GAVI) (2). 
We undertook a systematic review to determine the prevalence of HPV following 
HPV vaccination in women. The review will be of potential interest in a number of 
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areas globally, especially developing countries which are yet to adopt national HPV 
vaccination. The review data could be used to help to inform the importance of HPV 
vaccination among the recommended age range in a future national vaccination 
programme. While developing countries benefit from overall, developed countries on 
the other hand, could also still benefit from this study by highlighting some remaining 
questions about the indirect impacts of current and future HPV vaccines. The 
population effectiveness of HPV vaccines is an active area of research; we therefore 
review the currently available evidence on HPV vaccine uptake among women to 
prevent HPV infection. 
1.1 Objective  
The review seeks to assess the prevalence of HPV following HPV vaccination in 
women.  
2 Methods  
This systematic review employed scientific techniques and guidelines. The protocol 
was published in the PROSPERO International Prospective Register of systematic 
reviews 
(http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017058845) 
, registration number CRD 42017058845. 
2.1 Criteria for considering studies for this review  
The review considered studies using the following study designs: randomised 
controlled trials (RCTs), cohort studies, control before and after (CBA), interrupted 
time series (ITS) and cross-sectional studies. 
Studies were excluded if; 
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1. They did not report HPV prevalence in vaccinated women. 
2. Studies did not specify prevalence by gender in the vaccinated. 
3. Studies were duplicates. 
2.2 Types of participants  
The review only considered studies reporting HPV prevalence of females older than 
9 years who had received HPV vaccine. The age of 9 years is selected since it is the 
recommended starting age to receive HPV vaccine in the adolescent phase. There is 
no maximum age limit. The participants could be from any part of the world. 
2.3 Types of interventions  
To date three HPV vaccines are available; all the recommended HPV vaccines 
(quadrivalent, bivalent, and nonavalent vaccines) are considered as intervention, any 
HPV vaccine is therefore considered as intervention. Vaccines may have been 
administered intramuscularly or otherwise within a variation of intervals in 
recommended doses (3,11)  
2.4 Types of outcome measures  
2.4.1 Primary outcomes  
Proportion of females who developed HPV infection following vaccination.  
2.4.2 Secondary outcomes  
• Vaccination coverage, that is, the proportion of females who have received 
the recommended dose of the vaccine in a study.  
• Prevalence of cross protective HPV types following HPV vaccination 
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2.5 Search methods for identification of studies  
We developed a comprehensive search strategy to search for both published and 
unpublished articles, with no restrictions on language or publication date. The 
strategy included Medical Subject Headings (MeSH) and free-text terms relating to 
HPV vaccination uptake globally. The strategy was adapted to suit each individual 
database using applicable controlled vocabulary. The imported articles from various 
search results were managed with the Mendeley referencing software (Copyright © 
2009-2013 Mendeley Ltd). 
2.5.1 Electronic searches 
In this review, the following peer reviewed electronic databases were searched for 
eligible studies: PubMed, Cochrane Central Register of Controlled Trials, Scopus, 
Web of Science, World Health Organisation Library Information System (WHOLIS), 
Africa Wide and Current Nursing and Allied Health Literature (CINAHL). In addition, 
we also searched websites and databases for grey materials like World Health 
Organisation (WHO) (http://www.who.int/), United Nations Children’s Funds 
(UNICEF) (http://www.unicef.org/), Global Alliance for Vaccine and Immunisation 
(GAVI), (http://www.gavialliance.org/), US Centers for Disease Control and 
Prevention (CDC) (http://www.cdc.gov/), Program for Appropriate Technology in 
Health (PATH) Vaccine Resources Library (http://www.path.org/)The communication 
initiative network (http://www.comminit.com/), http://www.nyam.org/library, 
http://www.opengrey.eu/ and http://www.eldis.org/, Immunisation basics 
(http://www.immunizationbasics.jsi.com/ Index.html). Reference lists of relevant 
reviews and all eligible papers were also searched for relevant studies. Both 
published and unpublished studies were considered in the search.  
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2.6 Data collection and analysis  
2.6.1 Selection of studies  
Two authors (PM, LA) independently screened abstracts and titles identified in the 
search results for eligible studies. The full-text of studies that were eligible for 
inclusion were retrieved for assessment. Two (LA, PM) authors reviewed the studies 
independently and applied inclusion criteria to the retrieved studies. Differences were 
resolved through consensus between the two review authors. A third author’s (ME) 
opinion was sought when consensus was not reached. 
2.6.2 Data extraction and management  
Two review authors (PM, LA) independently carried out data extraction using a 
purpose designed data extraction form. Disagreements were resolved by consensus 
and a third author resolved the issues. Prior to use, the extraction form was piloted 
on at least four studies identified randomly from the list of included studies. The data 
collected included the study setting (country the study was undertaken), the study 
design, the type of participants, in this case women, vaccine type and details of 
outcome which includes prevalence of HPV in vaccinated women. 
2.7 Assessment of risk of bias in included studies  
We employed the quality assessment tool for evaluating prevalence studies as 
suggested by Hoy and adapted by Werfalli and colleagues (19,20). The quantitative 
scoring system of the Risk of Bias criteria allocates four points for external validly 
and six points for internal validity. Each of 10 domains are given a score of “1” if free 
of bias and “0” if bias is deemed to be present. The scoring system tool categorises 
high-risk studies as those with an overall score of 0-5 points, moderate risk as 6-8 
and low risk > 8 points. Two review authors (PM, LA) applied the risk of bias criteria 
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and discussed any disagreements through discussion and consensus, with the 
mediation of a third review (ME) when required. Table 2 shows the assessment 
criteria used. 
Table 2: Assessment criteria quality score 
External validity 
Point 
1. Was the study's target population a close representation of the national 
population in relations to relevant variables 
1 
2. Was the sampling frame a true or close representation of the target 
population? 
1 
3. Was some form of random selection used to select the sample, or was a 
census undertaken? 
1 




1. Were data collected directly from the participants (as opposed to a 
proxy)? 
 
2. Was an acceptable case definition used in the study? 
1 
3. Was the study instrument that measured the parameter of interest 
shown to have validity and reliability? 
1 
4. Was the same mode of data collection used for all participants? 
1 
5. Was the length of the shortest prevalence period for the parameter of 
interest appropriate? 
1 




Table 3 shows the risk assessment scale. Moderate risk means that “further 
research is likely to have an important impact on our confidence in the estimate of 
effect and may change the estimate” (20). Evidence is considered of low certainty if 
“further research is very likely to have an important impact on our confidence in the 
estimate of effect and is likely to change the estimate”, and very low certainty if “we 
have very little confidence in the effect estimate”(21). 
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Table 3: Risk assessment scale 
Quality scale Points 
Low risk   >8 points 
Moderate risk 6-8 points 
High risk 0-5 points 
2.8 Dealing with missing data  
Where essential, the authors of the studies were contacted to obtain missing data. In 
this review most of the studies were clear, one study however was not clear and the 
author was contacted for clarification. 
2.9 Assessment of heterogeneity  
Variation in study results due to differences in the type of intervention, the type of 
setting and study design and risk of bias, are described to assess the extent of 
variation between studies included in the systematic review. Statistical heterogeneity 
between study results was assessed using the chi-squared test of homogeneity with 
a 10% level of significance cut off. The I² statistic was used with values of 25% 
reflecting low heterogeneity, 50% medium heterogeneity and 75% high 
heterogeneity.  
2.10 Data synthesis  
Data synthesis comprised two steps. The first, was to identifying data sources, 
documenting the numerators and denominators that were used for calculating 
prevalence. The second step used the Freeman-Tukey double arcsine 
transformation to stabilise the variance of study prevalence using Stata® (version 
13.1). The stabilisation of variance helps to minimise influence from studies with 
outliers before the data is pooled together. Stratification of the data was done by 
continent and HPV type.  
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2.11 Ethics 
Ethical clearance was obtained from the Health Research committee from the 
University of Cape Town. This however was not a formal ethical review as 
systematic reviews draw on publicly available data. 
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3.1 Description of studies 
We retrieved, in total 2536 records, of which 1651 were from electronic published 
databases, 885 from the grey literature, hand searches and conference proceedings. 
After removing 856 duplicate records, 1680 remained from which 1652 were 
excluded based on title and abstract. The full-text records for the remaining 28 
studies were obtained for detailed evaluation after which, a further 15 records were 
excluded for various reasons (not having a vaccinated population or, lack of clarity 
between prevalence of vaccinated and unvaccinated and correlational data). Finally, 
13 studies met with our inclusion criteria. Studies excluded are listed with reasons in 
table 5. Only studies which showed clear numerators and denominators were 
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Figure 1: PRISMA Flow diagram 
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through other sources  
(n = 885) 
Records after duplicates removed  
(n = 1680) 
Records screened  
(n =1680) 
Records excluded  
(n = 1652) 
Full-text articles 
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Population not vaccinated 
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Prevalence not linked to 
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Results are correlational 
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3.2 Characteristics of included studies 
Table 4 provides a summary of the studies included in this review. The most 
common study design was cross sectional (10 studies, n=4839) (22–31) followed by 
randomised controlled trials (2 studies, n=3418) (32,33) and a single cohort study 
(n=75) (34). The age of participants ranged from 12 to 34 years. The studies were 
conducted in the United States of America (7 studies), Scotland (2 studies), Costa 
Rica (2 studies), Germany (1 study) and Australia (1 study).  
The 13 studies reported HPV prevalence following vaccination from 2004 to 
2013.The studies reported on vaccine HPV types HPV (6, 11, 16 and 18), cross 
protective HPV type (31, 33, 45, 51 & 58) prevalence, high risk HPV type (16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, 66 & 68) prevalence and overall HPV prevalence. 
No study had yet analysed the impact of the nonavalent vaccine on HPV prevalence 
in women as it was recently licenced in 2014.  
Ten studies (22–24,27,28,30–33) had a follow up sample representative of the 
originally vaccinated population while the remaining three (26,29,34) studies had 
samples not representative of the population.  
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Table 4: Summary of included findings 
Study ID Country Study design HPV vaccine type Post vaccine 
prevalence HPV (6, 










Age range Period 
North America  
Brogly 2014 USA Cross sectional design Quadrivalent 
Vaccine 
3% NS 96 235 21-30 years 2011-2012 
Cummings 
2012 
USA Cohort Quadrivalent 
Vaccine 
5% NS 75 75 20-29 years 2010 
Guo 2015 USA Cross sectional design Quadrivalent 
Vaccine 
7% 21% 177 878 18-25 years 2007-2012 
Herrero 2013 USA Randomised Controlled 
Trial 
Bivalent Vaccine 2% NS 2910 7466 13–26 years 2004-2005 
Markowitz 
2016 
USA Cross sectional design Quadrivalent 
Vaccine 
2% 51% 753 753 16–24 years 2009-2012 
Kahn 2012 USA Cross sectional design Quadrivalent 
Vaccine 
6% NS 409 409 20-21 years 2009-2010 




Bivalent Vaccine 6% NS 508 7466 14-34 years NS 
Schlecht 2012 USA Cross sectional design Quadrivalent 
Vaccine 
10% NS 513 645 10-24 years NS 
Tarney 2016 USA Cross sectional design Quadrivalent 
Vaccine 
4% 32% 340 1526 13-17 years  2007-2012 
   
Cameron 2016 Scotland Cross sectional design Bivalent Vaccine 10% 90% 1016 5765 14-17 years 2009-2013 
Delere 2014 Germany Cross sectional design Both quadrivalent 
and bivalent 
14% NS 223 787 20-25 years 2010-2012 
Kavanagh 
2014 
Scotland Cross sectional design Bivalent Vaccine 17% 90% 974 4679 22-29 years 2009-2012 
   
Tabrizi 2012 Australia Cross sectional design Quadrivalent 
Vaccine 
5% 55% 338 404 19-26 years 2011-2012 
ID, Identification; NS, Not Sated 
§ HPV vaccine coverage is defined as the proportion of women vaccinated in the eligible population 
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Table 5: Excluded studies 
Study ID Reason for exclusion for exclusion 
Brown 2009 No HPV prevalence data despite the population having been vaccinated for HPV. The focus was on cross-protective efficacy of the 
quadrivalent vaccine, 
Chow 2015 The study does not show separate data for vaccinated participants. 
Dunne 2015 The study does not show separate data for vaccinated participants despite mentioning that there was a low HPV prevalence in vaccinated 
participants 
Fischer 2016 The study does not specify whether participants were vaccinated. It makes assumptions that certain age groups may have been 
vaccinated. 
Hariri 2012 The paper describes HPV type distribution in US women aged 18–39 years reported to the HPV-IMPACT monitoring system with a 
diagnosis of CIN2+ during 2008–2009, prior to wide scale HPV vaccine introduction. 
Konopnicki 2016 The population not vaccinated, the study aimed to analyse the high-risk HPV genotype distribution in a cohort of HIV-positive women and 
to estimate the potential protection offered by the different HPV vaccines. 
Liu 2016 There was no HPV prevalence data following vaccination. The study describes the frequencies of adverse events following HPV 
vaccination among Alberta females 
Merckx 2014 The study presents analysis of correlational data that is not linked to vaccination registration 
Mesher 2015 The study only considers pre- vaccination and post vaccination prevalence without distinguishing those who had received vaccination in 
the post vaccine period. 
Mesher 2016 The study only considers pre- vaccination and post vaccination prevalence without distinguishing those who had received vaccination in 
the post vaccine period. 
Osborne 2015 The population included vaccinated and unvaccinated individuals, prevalence reported did not distinguish between vaccinated and 
unvaccinated. 
Powell 2012 The study included women who had already been advanced cervical lesions meaning they had already been pre- exposed to high risk 
HPV types 
Tota J.E 2016 The study explores the potential for type replacement, evaluating natural HPV type competition in unvaccinated females. 
Uhnoo 2014 The study followed HPV prevalence in Southern Sweden from 2008 to 2013 but did not report specifically in vaccinated women. 
Veldhuijzen 2015 The study does not clearly distinguish vaccinated women from unvaccinated. The study reports the age- and type-specific distribution of 
screen detected incident high-risk HPV infections among participants of two large European population based screening trials over the 
course of two screening rounds. 
 
Prudence Muusha: Journal manuscript   
 
Page 78 of 102 
 
3.3 Assessment of risk of bias in included studies 
No study was deemed as having a high risk of bias. Three studies were of low risk, 
and ten of moderate risk bias (Table 6). 
Two studies (32,33), indicated randomised sampling, while for the remaining studies 
the sampling method was not randomised. Since HPV testing requires vaginal swab 
samples or a cytological test obtained from individuals in order to make a diagnosis, 
all studies were collected directly from participants instead of a proxy and response 
bias was minimal as only one of 13 studies showed likelihood of response bias.  
An acceptable case definition was used in all studies; all studies indicated using a 
reliable instrument to measure the parameter of interest; all studies clearly indicated 
HPV data from women of the ages 12 years and above; all studies used a consistent 
mode of data collection for all subjects. Given the risk of bias in the studies reviewed, 
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Table 6: Risk Assessment 
 Study ID Internal Validity External validity     






















Risk of bias 
Brogly 2014           8 moderate risk 
Cameron 2016           8 moderate risk 
Cummings 2012           6 moderate risk 
Delere 2014           8 moderate risk 
Guo 2015           7 moderate risk 
Herrero 2013           9 low risk 
Kahn 2012           7 moderate risk 
Kavanagh 2014           8 moderate risk 
Kuhs 2014           8 moderate risk 
Markowitz 2016           9 low risk 
Schlecht 2012           7 moderate risk 
Tabrizi 2012           8 moderate risk 
Tarney 2016           9 low risk 
 
Table 6 shows risk of bias assessment for each individual study; 0-5 high risk of bias; 6-8 moderate risk of bias; >8 Low risk of bias. 
Symbol  represents 1 point indicating no bias while the  symbol represents 0 indicating bias in the study.
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4. Quantitative data synthesis 
4.1 Prevalence of vaccine type HPV (6, 11, 16 & 18) 
Thirteen studies with 8332 women vaccinated with the quadrivalent, bivalent or a 
combination of both vaccines, were analysed. HPV prevalence was 7% (95% CI: 5% 
to 9%, 13 studies, n=8332) for all the women who were vaccinated; test for 
heterogeneity, I 2 =95,5% (Figure 2). 
Subgroup analysis by continent indicates a prevalence in North America of 5% (95% 
CI: 3% to 7%, studies=9, n=5781) Europe, 14% (95% CI: 9 % to 18%, 3 studies, 
n=2213) and Australia, 5% (95% CI: 3% to 8%, 1 study, n=338). 
Figure 2: HPV prevalence by continent: Vaccine types (HPV 6, 11, 16 & 18)  
Heterogeneity between groups: p = 0.003
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4.2 HPV prevalence with cross protective HPV types (31, 33, 45, 51 & 58) 
Four studies with 3081 women were tested for HPV prevalence by HPV cross 
protective types (HPV 31, 33, 45, 51 & 58) (Figure 3). Overall, cross protective type 
HPV prevalence was 9% (95% CI: 6% to 12%, 4 studies, n=3081) in the women 
vaccinated; test for heterogeneity, I2 =89, 8%), North America had a statistically 
significant higher prevalence when compared to Europe or Australia. North America 
had a prevalence of 14% (95% CI: 12% to 17%, 1 study, n=753), Europe, 7% (95% 
CI: 6% to 8%, 2 studies, n=1990) and Australia, 8% (95% CI: 5% to 11%, study=1, 
n=338). 
Figure 3: HPV prevalence by continent: Cross protective types (31, 33, 45, 51 & 
58) 
Heterogeneity between groups: p = 0.000
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4.3 HPV prevalence by non-vaccine any HPV risk type 
Nine studies report prevalence by non-vaccine HPV types in vaccinated women 
(Figure 4). The pooled estimate shows a prevalence of 46% (95% CI: 21% to 71%,9 
studies, n=6784), test for heterogeneity, I 2=99,8%. 
When considered by continent, prevalence in North America was 43% (95% CI: 13% 
to 73%, 6 studies, n=4420), Europe, 56% (95% CI: 54% to 58%, 2 studies, n=1990) 
and Australia, 46% (95% CI: 41% to 52%, 1 study, n=338). 
 Figure 4: HPV prevalence by continent: non-vaccine any HPV risk type 
Heterogeneity between groups: p = 0.931
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4.4 HPV prevalence by high risk non-vaccine HPV types (31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 66 & 68), 
Figure 5 shows prevalence by high risk non-vaccine HPV types (HPV 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, 66 & 68); these are HPV types considered as high risk for 
disease but not currently covered by the vaccines administered in the studies in this 
review. Ten studies with 7088 women reported high risk non-vaccine HPV 
prevalence, and our pooled analysis found an overall estimated prevalence of 29% 
(95% CI: 14% to 43%, 10 studies, n = 7088); test for heterogeneity, I 2 =99,6%. 
When prevalence was considered by continent, North America had 27% (95% CI: 
10% to 43%, 7 studies, n=4760), Europe had 34% (95% CI: 32% to 36%, 2 studies, 
n=1990); Australia 31% (95% CI: 26% to 36%, 1 study, n=338). 
Figure 5: HPV prevalence by continent: High risk non-vaccine HPV types (31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, 66 & 68) 
Heterogeneity between groups: p = 0.299
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4.5 HPV (6, 11, 16 and 18) prevalence by study design 
We considered HPV vaccine type prevalence by study design, 13 studies with 8332 
vaccinated young women were analysed (Figure 6).  
Cross sectional studies had a prevalence 8% (95% CI: 5% to 11%, 10 studies, 
n=4839); Cohort studies 5% (95% CI: 1% to 13%, 1 study, n=75) and RCT 6% (95% 
CI: 4% to 8%, 2 studies, n=3418) 
Figure 6: HPV Prevalence (6, 11, 16 & 18) by study design 
Heterogeneity between groups: p = 0.002
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4.6 HPV vaccine coverage 
A limited number of studies reported on HPV vaccine coverage. Figure 7 considers 
vaccination coverage versus vaccine type HPV prevalence following vaccination.  
Figure 7: Vaccine coverage and HPV (6, 11, 16 and 18) prevalence 
 
Vaccination coverage varied widely across studies, the lowest coverage reported is 
21% while the highest is greater than 90%. The highest vaccine type prevalence was 
in a study that reported the highest HPV vaccine coverage whilst the lowest HPV 
vaccine type prevalence of 2% was reported in a study that had 51% coverage. 
Five of the seven studies which reported on vaccine coverage met with the minimum 
suggested threshold of 50% (16). Prevalence of HPV in the studies ranged from 17% 
to 25%. The remaining studies with vaccination coverage of 21% and 32% 
respectively nevertheless compared favourably in terms of HPV prevalence. We 
suspect that these data are insufficient from which to draw conclusions on the 
correlation between coverage and prevalence. 
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Our original intention was to evaluate cost of intervention, adverse events following 
immunisation and, adverse effects of the intervention; however, we found no data in 
the included studies to allow for this.   
 
5. Discussion and conclusion 
The HPV vaccine development has been hailed as a major advancement of 
women’s health. Since the vaccine was first introduced in 2006, the world has been 
waiting to see its impact on HPV infection and, subsequent cervical cancer. 
However, cervical cancer usually develops in the third decade of life, meaning that 
the impact of HPV vaccination will only be accurately measured 30 years after 
vaccine introduction. In the meantime, a good measure of the vaccine effectiveness 
and a good proxy for cervical cancer are high risk HPV types known to cause 
cancer. Thus far many studies have been conducted considering HPV vaccination in 
the population following HPV vaccination. 
This review found a pooled HPV prevalence of 7% amongst women, globally, 
vaccinated with HPV 6,11,16,18 subtypes. At a continental level the prevalence was 
higher in Europe at 14% when compared with North America or Australia where HPV 
vaccine coverage was 59% and 73% respectively. High income countries account for 
approximately 70% of the vaccinated population worldwide and have globally 
achieved less than 50% coverage (16). HPV vaccination coverage could therefore 
have had minimal impact on HPV prevalence. HPV prevalence in unvaccinated 
women within the 34 years and younger age band was previously reported to be as 
high as 21%, this age band is reported have the highest prevalence (35). When 
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compared to the pre-HPV vaccine study our study shows a reduction in HPV 
prevalence as a result of vaccination. 
This review, to our knowledge the first of its kind, represents a comprehensive 
attempt at synthesising available data on HPV prevalence in vaccinated women; 
multiple databases were searched with no language restrictions and, employing 
stringent inclusion criteria. However, we acknowledge several limitations that could 
have impacted on this review. Participants were influenced by study design, for 
example, all RCTs did not have a representative sample. Some studies used 
samples taken from women attending regular gynaecological tests which may have 
influenced HPV prevalence in that women going for gynaecological tests could 
already have existing symptoms indicative of HPV-related infections.  
All 13 studies had the age group required in our inclusion criteria of ten years or 
older. Of studies initially considered, fifteen were removed as they did not meet 
inclusion criteria in that, despite measuring vaccine prevalence following vaccination, 
they did not specifically measure prevalence in women who were vaccinated. A 
further study was excluded from analysis despite being considered eligible as the 
women had advance cervical lesions which already meant pre-exposure to high risk 
HPV types.  
In the analysis we looked at vaccine coverage and study designs in relation to 
vaccine type prevalence. It is interesting that high vaccine coverage reported did not 
always translate to low vaccine type prevalence. Analysis by study design also 
interestingly revealed that HPV vaccination is effective even under non-RCT 
conditions where follow up is more stringent. 
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HPV vaccination has been proven to have cross protective abilities for vaccine types 
(HPV 31, 33, 45, 51 & 58). Studies reporting on cross protective HPV types together 
showed a prevalence of 9%; the sample size was 3081 women. One study included 
in our analysis reported prevalence of cross protective types having reduced from 
13% before vaccination to 6% following vaccination (24). There is still some debate 
around HPV vaccine  on the non-vaccine types; however most studies report 
moderate to high significance in reduction while one large study in the USA saw no 
evidence in reduction of cross protective types, explained to possibly be as a result 
of low vaccine coverage (17,36,37). 
We also considered HPV prevalence of high risk HPV subtypes not included 
amongst those incorporated into the vaccines. The pooled estimate of 29% for this 
subgroup was significantly higher than the 7% amongst recipients of the HPV 
vaccine against subtypes 6, 11, 16 and 18. Of note, one of the studies pooled for the 
analysis reported a prevalence of 54% (24).   
HPV prevalence in vaccinated women by non-vaccine any HPV risk types was 42%. 
Our results contrasts greatly to those reported of in  meta-analysis results of world 
HPV prevalence, found to be much less at 10,1% (7). This may be because our 
analysis, included a narrow age band from 12 – 34 years old; this age group is likely 
to have the highest prevalence since sexual debut is a risk factor for HPV infection 
leading to a HPV peak prevalence in young women (6). The prevalence in our study 
remained considerably higher when considering the continental breakdown; North 
America 42% compared to 4,7% and Europe 43% compared to 14,2% (7).   
As part of our secondary outcomes we sought to assess the cost of interventions 
and adverse events following immunisation and adverse effects of the intervention. 
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None of the articles that fit our selection criteria reported this information as a result 
we will not be reporting on them. 
The findings for this review provides world-wide a snapshot of vaccination 
performance in possibly reducing diseases such as cervical cancer. This information 
will be useful to policy makers and implementers on issues around cost 
effectiveness, priority age groups and vaccines to use. It is necessary to still 
continue monitoring HPV incidences in vaccinated populations especially in 
countries where vaccine coverage is high, developing countries are said to be doing 
better in vaccine coverage than developed countries whose data contribute to this 
study. HPV prevalence in developing countries will likely to change if high coverage 
persists, thus it will be interesting to see the direction prevalence will take. 
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whether this was done at the study or outcome level), and how this information is to be used in 
any data synthesis.  
73 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).   
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis.  
75 
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PLOS Style and Format 
 
File format Manuscript files can be in the following formats: DOC, DOCX, RTF, 
or PDF. Microsoft Word documents should not be locked or 
protected.  
Length Manuscripts can be any length. There are no restrictions on word count, 
number of figures, or amount of supporting information. 
Font Use a standard font size and any standard font, except for the font 
named “Symbol”.  
Headings Limit manuscript sections and sub-sections to 3 heading levels. Make 
sure heading levels are clearly indicated in the manuscript text. 
Layout and 
spacing 
Manuscript text should be double-spaced. Do not format text in multiple 
columns. 
Page and line 
numbers 
Include page numbers and line numbers in the manuscript file. Use 
continuous line numbers (do not restart the numbering on each page). 
Footnotes Footnotes are not permitted. If your manuscript contains footnotes, move 
the information into the main text or the reference list, depending on the 
content. 
Language Manuscripts must be submitted in English.  
Abbreviations Define abbreviations upon first appearance in the text. Do not use non-
standard abbreviations unless they appear at least three times in the text. 
Keep abbreviations to a minimum. 
Reference 
style 
PLOS uses “Vancouver” style, as outlined in the ICMJE sample 
references. 
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The following elements are required, in order: 






The following elements can be renamed as needed and presented in any 
order: 
• Materials and Methods 
• Results 
• Discussion 
• Conclusions (optional) 
Ending 
section 
The following elements are required, in order: 
• Acknowledgments 
• References 
• Supporting information captions (if applicable) 
Other 
elements 
• Figure captions are inserted immediately after the first paragraph 
in which the figure is cited. Figure files are uploaded separately. 
• Tables are inserted immediately after the first paragraph in which 
they are cited. 
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• Supporting information files are uploaded separately. 
 
Systematic reviews and meta-analyses 
Reports of systematic reviews and meta-analyses must include a completed 
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 
checklist and flow diagram to accompany the main text. Blank templates are 
available here: 
Authors must also state in their “Methods” section whether a protocol exists for their 
systematic review, and if so, provide a copy of the protocol as supporting information 
and provide the registry number in the abstract. 
If your article is a systematic review or a meta-analysis you should: 
• State this in your cover letter 
• Select “Research Article” as your article type when submitting 
• Include the PRISMA flow diagram as Fig 1 (required where applicable) 
• Include the PRISMA checklist as supporting information 
 
 
